151. Rasmussen encephalitis Clinical trials / Disease details
Clinical trials : 2 / Drugs : 4 - (DrugBank : 2) / Drug target genes : 6 - Drug target pathways : 86
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04003922 (ClinicalTrials.gov) | October 20, 2020 | 20/6/2019 | Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term | Observational Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term | Rasmussen Encephalitis | Other: Adalimumab treatment | Assistance Publique Hopitaux De Marseille | NULL | Recruiting | 2 Years | N/A | All | 40 | France |